



◆ **DRXT28s05 (iPS cells expressing the third highest HLA in Japan※1)**

Clone ID	DRXT28s05	Product	Human iPS cells
Source	Peripheral Blood, Human	Race	Japanese
Passage No.	9	Gender	Male
Lot No.	20170715-08	Manufacture Dates	July 15 th , 2017
Culture medium	StemFit AK03N	Substrate	iMatrix-511MG
Culture Method	Feeder-free (※2)		
Plasmids for reprogramming	pCE-hSK, pCE-hUL, pCE-hOCT3/4, pCE-mp53DD, pCXB-EBNA1		
Use and Provision of this cell stock	Please check our web site ; https://www.cira-foundation.or.jp/e/project/stock.html		

(※1) Reference; Okita, *et. al.*, Nat Methods. 2011 8(5): 409-412

(※2) Reference; Nakagawa, *et. al.*, Nat Biotechnol. 2008 26(1):101-106

Test Result

Test	Method	Result
Sterility	BacT/ALERT	Negative
Mycoplasma	PCR	Negative
Endotoxin	LAL	≤ 5 EU/mL
Virus (HBV, HCV, HIV, HTLV, Parvovirus B19)	PCR	Negative
HLA typing (HLA-A, B, DR)	PCR-SBT	Consistent with the donor cells
STR genotyping	PCR	Consistent with the donor cells
Morphology	Microscope	Consistent with human ES cells
Karyotype	Conventional Giemsa analysis G-banding	46,XY[20]
Plasmid remnants	qPCR	Below the limit of quantification
CNV(※3)	WGS, SNP	No de novo CNVs (>1kbp) were found in COSMIC Cancer Gene Census (ver.83) and Shibata list(※5) .
SNV/Indel(※4)	WGS, WES	No de-novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.83) and Shibata list(※5) .
Undifferentiated markers	Microarray(※7)	<i>POU5F1</i> : 5.4%、 <i>NANOG</i> : 11.0% (Relative expression levels of <i>GAPDH</i>)
	Flow cytometry (※7)	TRA-1-60: 96.8% SSEA4: 99.6% TRA-2-49: 99.8%

Thawed postnatal cells	Counting the number of the cells (※6, 7)	1.88×10^5 cells (Survival rate ; 92.0%)
Number of proliferating cells after thawing	Counting the number of the cells after culturing for 6 days(※6, 7).	8.3×10^5 cells (Number of seeded cells : 1.80×10^5 cells)
Doubling time (h)	Counting the number of the cells (※6, 7)	P12→P13: 31.4 P13→P14: 28.5 P14→P15: 29.2 P15→P16: 27.4 P16→P17: 26.5

(※3) CNV; Copy Number Variation


(※4) SNV/Indel; Single nucleotide variants /Insertion Deletion

(※5) The PMDA Science Board “Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials” (Cellular- and Tissue-based Products Subcommittee, 20 August 2013)

(※6) ThermoFisher Countess®

(※7) The result of # 1 out of 3 frozen stocks is shown.

■ Image



Please contact us if you have any questions.

(ips-request@cira-foundation.or.jp)